市场调查报告书
商品编码
1467891
消化性溃疡药物市场依产品类型(质子帮浦抑制剂、钾竞争性酸阻断剂、抗酸剂、H2拮抗剂、抗生素、溃疡保护剂)、溃疡类型、配销通路和地区2024-2032年Peptic Ulcer Drugs Market by Product Type (Proton Pump Inhibitors, Potassium-Competitive Acid Blocker, Antacids, H2-Antagonists, Antibiotics, Ulcer protective), Ulcer Type, Distribution Channel, and Region 2024-2032 |
IMARC Group年全球消化性溃疡药物市场规模达48亿美元。消化性溃疡的盛行率不断增加,尤其是在老年族群中,以及消费者倾向于使用各种药物而不是侵入性手术,这是推动市场发展的一些关键因素。
消化性溃疡或十二指肠溃疡是一种开放性溃疡,逐渐发展并引发胃、小肠和下食道内壁的缺陷。它们通常是由于发炎、放射治疗、频繁口服和注射阿斯匹灵以及抗发炎药物引起的。如果消化性溃疡未及时治疗,可能会引起中上身剧烈疼痛、体重减轻、内出血和严重失血,需要住院治疗。目前,他们可以用多种药物类型进行治疗,包括质子帮浦抑制剂(PPI)、H2拮抗剂、抗生素、钾竞争性酸阻断剂(P-CAB)、抗酸剂和溃疡保护剂。这些药物可以减轻身体疼痛,提供更多的癒合时间,最大限度地减少胃酸分泌,抵抗细菌感染,并保护胃免受消化液的侵害。因此,消化性溃疡药物被医疗保健从业人员广泛用于治疗胃炎、胃食道逆流(GERD)和十二指肠溃疡。
消化性溃疡的盛行率不断增加,特别是在老年族群中,是推动市场成长的关键因素之一。此外,不健康的生活习惯和胃癌发病率的上升,导致越来越多的人患有消化性溃疡。再加上消费者对各种消化性溃疡治疗药物而非侵入性手术的倾向不断变化,这反过来又促进了市场的成长。与此一致的是,与外科手术相比,几种类固醇抗发炎药物具有微创性、更实惠,并且可以在确保减少失血的同时实现更快的恢復。此外,消化性溃疡药物的持续批准以及政府对製药公司的药物配方投资也支持了市场的成长。这进一步受到持续进行新药形成临床试验以克服併发症和市面上现有药物无效的影响。此外,消费者越来越意识到经济高效的消化性溃疡药物的好处及其在多个分销管道上的便利性,这有利于市场的成长。用于执行诊断和法医操作的基于人工智慧(AI)的病理测试技术的出现也推动了市场的成长。其他因素,例如为提高产品功效而进行的广泛研发(R&D)活动以及增加用于开发治疗消化性溃疡的非处方(OTC)药物的投资,正在对市场成长产生积极影响。
The global peptic ulcer drugs market size reached US$ 4.8 Billion in 2023. Looking forward, IMARC Group expects the market to reach US$ 6.1 Billion by 2032, exhibiting a growth rate (CAGR) of 2.65% during 2024-2032. The increasing prevalence of peptic ulcers, especially amongst the geriatric population and shifting consumer inclination toward various medications over invasive surgeries represent some of the key factors driving the market.
Peptic ulcers, or duodenal ulcers, are open sore that gradually develops and triggers defects in the lining of the stomach, small intestine, and lower esophagus. They are usually caused due to inflammation, radiation therapy, frequent oral and injectable administration of aspirins, and anti-inflammatory drugs. If peptic ulcers are left untreated, they might initiate severe pain in the mid- or upper-body parts, weight loss, internal bleeding, and severe blood loss, which require hospitalization. Currently, they can be treated with various drug types, including proton pump inhibitors (PPI), H2 antagonists, antibiotics, potassium-competitive acid blockers (P-CAB), antacids, and ulcer protectives. These medications reduce body aches, provide more time to heal, minimize acid secretion, offer resistance against bacterial infections, and protect the stomach from digestive juices. As a result, peptic ulcer drugs are extensively utilized by healthcare practitioners for the treatment of gastritis, gastroesophageal reflux disease (GERD), and duodenal ulcers.
The increasing prevalence of peptic ulcers, especially amongst the geriatric population, represents one of the key factors driving the market growth. Moreover, unhealthy lifestyle habits and rising instances of stomach cancer, is resulting in the growing number of individuals suffering from peptic ulcers. This, along with the shifting consumer inclination towards various peptic ulcer-curing drugs over invasive surgeries, which, in turn, is contributing to the market growth. In line with this, as compared to surgical procedures, several steroidal anti-inflammatory medications are minimally invasive, more affordable, and enable faster recovery while ensuring reduced blood loss. Additionally, the ongoing approvals of peptic ulcer drugs and several government investments in pharmaceutical companies for the formulation of medications are supporting the market growth. This is further influenced by the continuous conduction of clinical trials for new drug formation to overcome complications and the ineffectiveness of present drugs in the market. Moreover, the increasing consumer awareness regarding the benefits of cost-effective peptic ulcer drugs and their easy availability across multiple distribution channels is favoring the market growth. The advent of artificial intelligence (AI)-based pathology testing technology to perform diagnostic and forensic operations is also propelling the market growth. Other factors, such as extensive research and development (R&D) activities to enhance product efficacy and the increasing investments in the development of the over the counter (OTC) medications for treating peptic ulcers, are positively impacting the market growth.
IMARC Group provides an analysis of the key trends in each segment of the global peptic ulcer drugs market, along with forecasts at the global, regional, and country level from 2024-2032. Our report has categorized the market based on product type, ulcer type, and distribution channel.
Proton Pump Inhibitors
Potassium-Competitive Acid Blocker (P-CAB)
Antacids
H2-Antagonists
Antibiotics
Ulcer protective
The report has also provided a detailed breakup and analysis of the peptic ulcer drugs market based on the product type. This includes proton pump inhibitors, potassium-competitive acid blocker (P-CAB), antacids, H2-antagonists, antibiotics, and ulcer protective. According to the report, antibiotics represented the largest segment.
Gastric Ulcer
Duodenal Ulcer
Others
A detailed breakup and analysis of the peptic ulcer drugs market based on the ulcer type has also been provided in the report. This includes gastric ulcer, duodenal ulcer, and others. According to the report, duodenal ulcer accounted for the largest market share.
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
The report has also provided a detailed breakup and analysis of the peptic ulcer drugs market based on the distribution channel. This includes hospital, retail and online pharmacies. According to the report, hospital pharmacies represented the largest segment.
North America
United States
Canada
Asia Pacific
China
Japan
India
South Korea
Australia
Indonesia
Others
Europe
Germany
France
United Kingdom
Italy
Spain
Russia
Others
Latin America
Brazil
Mexico
Others
Middle East and Africa
The report has also provided a comprehensive analysis of all the major regional markets that include North America (the United States and Canada); Asia Pacific (China, Japan, India, South Korea, Australia, Indonesia, and others); Europe (Germany, France, the United Kingdom, Italy, Spain, Russia, and others); Latin America (Brazil, Mexico, and others); and Middle East and Africa. According to the report, North America was the largest market for peptic ulcer drugs. Some of the factors driving the North America peptic ulcer drugs market included the increasing prevalence of peptic ulcers, especially amongst the geriatric population and shifting consumer inclination toward various peptic ulcer curing drugs over invasive surgeries and the fueling need for over-the-counter (OTC) medications in the healthcare sector.
The report has also provided a comprehensive analysis of the competitive landscape in the global peptic ulcer drugs market. Detailed profiles of all major companies have also been provided. Some of the companies covered include Abbott Laboratories, AstraZeneca plc, Boehringer Ingelheim International GmbH, Novitium Pharma LLC, Pfizer Inc., PharmaKing Co. Ltd., RedHill Biopharma Ltd, Viatris Inc., Yuhan Corporation, Zydus Lifesciences Limited, etc. Kindly note that this only represents a partial list of companies, and the complete list has been provided in the report.
Kindly, note that this only represents a partial list of companies, and the complete list has been provided in the report.